Tasigna((R)) (Nilotinib) Preliminary Results of Settling Studies ENESTfreedom and ENESTop remain more than Half of the participating CML Patients in therapy-free Remission

首页> 外文期刊>Oncology research and treatment. >Tasigna((R)) (Nilotinib) Preliminary Results of Settling Studies ENESTfreedom and ENESTop remain more than Half of the participating CML Patients in therapy-free Remission

【24h】

Tasigna((R)) (Nilotinib) Preliminary Results of Settling Studies ENESTfreedom and ENESTop remain more than Half of the participating CML Patients in therapy-free Remission

机译：Tasigna（R）（尼洛替尼）沉降研究的初步结果ENESTfreedom和ENESTop仍占参与治疗的CML患者无治疗缓解的一半以上

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Oncology research and treatment.》 |2016年第8期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Tasigna((R)) (Nilotinib) Preliminary Results of Settling Studies ENESTfreedom and ENESTop remain more than Half of the participating CML Patients in therapy-free Remission [J] . Oncology research and treatment. . 2016,第7a8期

机译：Tasigna（R）（尼洛替尼）沉降研究的初步结果ENESTfreedom和ENESTop仍占参与治疗的CML患者无治疗缓解的一半以上
2. Treatment-Free Remission (TFR) Following Frontline Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): 192-Weeks Data from the ENESTfreedom Study [J] . Radich Jerald P., Ross David M., Masszi Tamas, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：在慢性期慢性骨髓白血病患者的前线NILOTINIB（CML-CP）中的无治疗缓解（TFR）：来自Enestfreedom研究的192周数
3. ENESTop 192-Weeks Results: Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib [J] . Mahon Francois-Xavier, Boquimpani Carla, Takahashi Naoto, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：192周的结果：在停止第二线Nileotinib后慢性骨髓白血病患者的免疫缓解（TFR）慢性相（CML-CP）。
4. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study [O] . A Hochhaus, T Masszi, F J Giles, -1

机译：慢性期慢性粒细胞白血病患者一线尼罗替尼治疗后的无治疗缓解：ENESTfreedom研究的结果
5. Faculty Opinions recommendation of Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. [O] . Daniela Krause 2021

机译：教师意见建议慢性骨髓白血病患者慢性骨髓性白血病患者的推荐慢性期：96周的Enestfreedom研究更新。

Tasigna((R)) (Nilotinib) Preliminary Results of Settling Studies ENESTfreedom and ENESTop remain more than Half of the participating CML Patients in therapy-free Remission

著录项

引文网络

相似文献

相关主题

期刊订阅